Assertio Therapeutics Pays $3.6 Million to Settle False Claims Act Allegations Over Fentanyl Marketing
Assertio Therapeutics has agreed to pay $3.6 million to resolve allegations tied to misleading marketing practices involving its fentanyl nasal spray, Lazanda. The settlement was announced by the Department of Justice on May 5, 2025, addressing claims that Assertio’s marketing led to false billing for prescriptions that were not medically justified.